96 results about "Neurologic injury" patented technology

The present invention relates to novel non-sedating barbituric acid derivatives, pharmaceutical compositions containing them and methods of neuroprotection in cases of cerebral ischemia, head trauma and other acute neurologic injuries, and prevention of resulting neuronal damage. The invention also relates to the use of non-sedating barbituric acid derivatives given in a manner and dosage effective to produce blood levels and brain levels of these drugs and/or their active metabolites sufficient to provide a therapeutic effect.

A method for treating neural damage with a composition prepared from roots of bupleurum and scutellaria.

The invention relates to a fibroin three-dimensional bracket for nervus centralis remediation, and belongs to the field of biological medicinal materials. The fibroin three-dimensional bracket comprises fibroin protein fiber with grooves, fibroin protein/hyaluronic acid plural gel and fibroin membrane conduits. By adopting the fibroin three-dimensional bracket, defects that a conventional bracket is low in mechanical property, low in biodegradability and the like are overcome. By adopting the fibroin three-dimensional bracket, physiological states of an extracellular matrix can be simulated, adhesion, migration, amplification and differentiation of cells can be facilitated, and furthermore orientated growth of axon to fracture parts can be guided; due to connection of the bracket, glial scars can be inhibited, and thus remediation of a nervus centralis system can be facilitated; and the bracket can be applied to basic research on neural injury remediation, can be also applied to bridging remediation of human body spinal cord injury or deficiency, and has good biomedical prospects.

The invention relates to the technical field of tissue engineering, in particular to a tissue engineering material for nerve injury repair as well as a preparation method and application of the tissueengineering material. The tissue engineering material for nerve injury repair is a linear ordered collagen stent of crosslinked N-cadherin. The tissue engineering material prepared by crosslinkingtheN-cadherin in the linear ordered collagen stent can efficiently induce neural stem cells to migrate towards an injury region, enrich neutral stem cells in the injury region, effectively inhibit deposition of inhibitors such as chondroitin sulfate proteolgycan and promote differentiation of the neutral stem cells towards neurons so as to promote recovery of electrophysiological and motion functions; and meanwhile, the N-cadherin crosslinked linear ordered collagen stent also has stable and ordered topological structures and excellent mechanical properties and thus can be used for repairing nerve injuries such as spinal cord injury.

The invention relates to a nerve repair drug-carrying system with bioelectrical stimulation and angiogenesis promoting effects and a preparation method thereof. Gelatin, chitosan, polylactic acid andother natural polymer components in the nerve repair drug-carrying system ensure good biocompatibility and no toxicity, polylactic acid can also meet the good mechanical property requirement of a catheter, catheter collapse in the nerve growth process is avoided, and excellent flexibility enables the nerve repair drug-carrying system not to hinder nerve regeneration. Due to the introduction of a conductive copolymer GO, the catheter has weak conductivity, meets the requirement of physiological current of a human body, and is beneficial to accelerating nerve repair; and by introducing a VEGF growth factor, an extracellular matrix microenvironment in a human body can be simulated to the maximum extent, nerve repair is promoted from the microvascular regeneration acceleration direction, and finally the nerve injury repair quality is improved.

The invention relates to an O-aryl glycoside derivative, a preparation method and application thereof in preparation of drugs or pharmaceutical compositions. The O-aryl glycoside derivative (I), its isomer, prodrug, solvate or pharmaceutically acceptable salt has a structure shown as the specification. The O-aryl glycoside derivative provided by the invention has good efficacy of treating ischemicnerve injury, especially has no strict time window limit in treatment of ischemic nerve injury after stroke molding, and can achieve continuous multiple dosing within 7 days to generate better efficacy.

The invention discloses a bitter gourd exosome, and an extraction method and application of same. Extraction comprises the following steps: taking fresh wild bitter gourds of Yunnan, removing seeds, and cleaning and drying the bitter gourds; obtaining bitter gourd juice by squeezing, centrifuging the bitter gourd juice continuously, taking the supernatant after centrifugation and discarding the sediment; conducting ultra-centrifugation of the obtained supernatant, discarding the supernatant, taking the sediment and suspending the sediment in a phosphoric acid buffer salt solution of 1-2mL; andfiltering the suspension with a 0.22 mum filtering film, centrifuging the filtrate in an ultra-centrifugation refrigeration machine for centrifugation again, discarding the supernatant, taking the sediment and suspending the sediment in the phosphoric acid buffer salt solution of 1-2mL. The extracted bitter gourd exosome can be used for preparing medicines of ischemic cerebral apoplexy. The extraction method disclosed by the invention is convenient and effective, the extraction purity is high, and the extracted bitter gourd exosome can protect nerve injuries after cerebral apoplexy.

The present invention provides a therapeutic agent for nerve damages such as those caused by spinal cord injury or nerve trauma, which comprises, as an active ingredient, a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof. The present invention also provides a therapeutic agent for nerve damages which comprises, as an active ingredient, preferably a low-molecular-weight hyaluronic acid, more preferably hyaluronic acid disaccharide to hyaluronic acid 2,500-saccharide, further more preferably hyaluronic acid disaccharide to hyaluronic acid 50-saccharide, much more preferably hyaluronic acid tetrasaccharide, or a pharmaceutically acceptable salt thereof.

The invention relates to a method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury including the step of administering an effective amount of a peptide comprising the sequence: GlyArgArgAlaAlaProGlyArgAibGlyGly (SEQ ID NO:1) or the sequence GlyArgArgAlaAlaProGlyArgAibGlyGly-HN2 (SEQ ID NO:2) to a subject in need thereof.

The present invention provides central nervous system neural progenitor cells which can induce neurons with synapse forming ability, oligodendrocytes, astrocytes and the like when transplanted into an injured or disabled spinal cord, a method for preparing said central nervous system neural progenitor cells, a method for screening promoters or inhibitors of synapse formation using said central nervous system neural system neural progenitor cells, a therapeutic drug to improve neural injuries or neural functions using said central nervous system neural progenitor cells, and the like. The central nervous system neural progenitor cells comprising neural stem cells derived from the spinal cord and cultured in the presence of cytokine, is transplanted into the injury site at a certain period after the spinal injury. The transplantation can induce neurons with synapse forming ability, oligodentrocyte, and astrocytes in the injury site, resulting in forming synapses between induced neurons and host neurons, and thus the injured spinal cord function is improved.

The invention discloses a tissue engineering nerve complex as well as a preparation method and application thereof, and belongs to the field of biomedical materials. The tissue engineering nerve complex comprises a nerve conduit, a fiber scaffold and an injectable shear thinning biological material, wherein the nerve conduit is filled with the fiber scaffold and the injectable shear thinning biological material; the injectable shear thinning biological material (VEGF-iSTB) is prepared from gelatin, nano silicate SNPs, a vascular endothelial growth factor and water. The tissue engineering nerve complex containing VEGF-iSTB is prepared by utilizing a VEGF-iSTB slow release system and is transplanted to the subcutaneous part of a host, so that the pre-vascularized tissue engineering nerve complex is constructed; then, the pre-vascularized tissue engineering nerve complex is used for transplanting and repairing long-distance defects of sciatic nerves of rats, fusion with a host vascular system after transplantation can be achieved, and then the nerve injury repairing effect is improved.

According to the invention, human induced pluripotent stem cells are differentiated into NSCs in vitro, human umbilical cords are separated and cultured into MSC auxiliary materials, the materials are used according to the proportion of 1: 1, PBS is used as a solvent, an obtained cell biological product is jointly transplanted to the spinal cord of a mouse with acute spinal cord injury (at the thoracic marrow T10 stage) in situ, nerve injury repair is effectively promoted, and the motor function is improved. The product for treating animal acute spinal cord injury can be differentiated into neurons and glial cells in the host body, reduce the glial scar area, reduce fibrosis and reduce the inflammation level, so that the animal motor function, especially limb coordination, is improved, and the product fully plays a role in subsequent treatment of the spinal cord injury and promotion of tissue repair.

The invention discloses circular RNA circ-01477 and an application thereof to preparation of drugs for promoting nerve regeneration and repairing nerve injuries. Research results indicate that by means of down-regulation or suppression of organism circ-01477 expression, proliferation and migration of astrocytes are suppressed, and repair of central nerve injuries is facilitated.

The invention relates to the technical field of nerve vertigo and discloses a cranial nerve injury patient vertigo protection mechanism. The mechanism comprises a shell, wherein an air bag is fixedly connected to the inner side of the shell, a connecting block is fixedly connected to the inner wall of the shell, an electrode column is fixedly connected to the inner wall of the connecting block, and a leather ring is fixedly connected to the outer side of the electrode column; an electric heating wire is fixedly connected to the inner side of the leather ring, a round hole is formed in an inner wall of the connecting block, an electromagnet is fixedly connected to the inner wall of the shell, and a limiting block is elastically connected to the position, close to the outer side of the electromagnet, of the inner wall of the shell. According to the vertigo protection mechanism for the cranial nerve injury patient, through explosion of sodium azide in the leather ring, when the cranial nerve patient is in a standing state, if vertigo occurs, the cranial nerve patient topples over, a head of the cranial nerve patient is prevented from colliding with the ground, damage to the head is avoided, and damage to the cranial nerve patient is relieved; and potential safety hazards in rehabilitation of cranial nerve patients are eliminated.

The invention discloses a tetrodotoxin compound preparation which comprises the following components: tetrodotoxin, lidocaine, puerarin and an excipient. The invention also discloses use of the tetrodotoxin compound preparation in the preparation of a medicament for treating neuropathic pain, wherein the neuropathic pain is diabetic peripheral neuropathic pain or neuropathic injury pain. The novel tetrodotoxin compound preparation provided by the invention is used for treating diabetic peripheral neuropathic pain and neuropathic injury pain, and has advantages of small toxic side effect, good analgesic effect and the like.

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

Disclosed are systems and methods for reducing blood pressure variability in a patient. The system includes an endovascular catheter having an expandable element and one or more blood pressure sensors, and a computer/processing unit configured to receive blood pressure measurements and determine a blood pressure variability metric. Upon determining that the blood pressure variability metric exceeds a given blood pressure variability threshold or falls outside a predefined range, the computer/processing unit directs a catheter controller to adjust the size of the expandable element of the catheter, thereby modulating blood pressure and reducing blood pressure variability.